# Anti-Hepatitis A Virus, Pharmacokinetics, and Safety of Immune Globulin (Human)

> **NCT03351933** · PHASE4 · COMPLETED · sponsor: **Grifols Therapeutics LLC** · enrollment: 28 (actual)

## Conditions studied

- Anti-Hepatitis A Antibody Levels in Heathy Subjects

## Interventions

- **BIOLOGICAL:** Immune Globulin (Human)

## Key facts

- **NCT ID:** NCT03351933
- **Lead sponsor:** Grifols Therapeutics LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-31
- **Primary completion:** 2018-04-27
- **Final completion:** 2018-07-19
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2019-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03351933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03351933, "Anti-Hepatitis A Virus, Pharmacokinetics, and Safety of Immune Globulin (Human)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03351933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*